Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.

Autor:	Kokkali S; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece stefaniakokkali@yahoo.com., Tripodaki ES; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Drizou M; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Stefanou D; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Magou E; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Zylis D; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Kapiris M; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Nasi D; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Georganta C; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece., Ardavanis A; First Medical Oncology Clinic, Saint Savvas Anticancer Hospital, Athens, Greece.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2018 May-Jun; Vol. 32 (3), pp. 653-657.
DOI:	10.21873/invivo.11289
Abstrakt:	Background/aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. We adopted a biweekly regimen with the same dose density. Patients and Methods: Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study. Study combination included 1.5 g/m 2 gemcitabine and 175 mg/m 2 nab-paclitaxel given every 2 weeks. Survival analysis was performed using the Kaplan-Meier method. Results: Forty-six patients were treated with this regimen. Adverse events were similar to those of the original regimen. Median progression-free and overall survival were 5 and 10 months, respectively. Conclusion: Biweekly gemcitabine/nab-paclitaxel seems to have a similar safety and efficacy profile as the original regimen. (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu